Giancarlo Agnelli

20.2k total citations · 7 hit papers
180 papers, 13.9k citations indexed

About

Giancarlo Agnelli is a scholar working on Internal Medicine, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Giancarlo Agnelli has authored 180 papers receiving a total of 13.9k indexed citations (citations by other indexed papers that have themselves been cited), including 135 papers in Internal Medicine, 101 papers in Cardiology and Cardiovascular Medicine and 50 papers in Surgery. Recurrent topics in Giancarlo Agnelli's work include Venous Thromboembolism Diagnosis and Management (135 papers), Atrial Fibrillation Management and Outcomes (72 papers) and Acute Myocardial Infarction Research (27 papers). Giancarlo Agnelli is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (135 papers), Atrial Fibrillation Management and Outcomes (72 papers) and Acute Myocardial Infarction Research (27 papers). Giancarlo Agnelli collaborates with scholars based in Italy, United States and Canada. Giancarlo Agnelli's co-authors include Alexander Gallus, Gary E. Raskob, Gary E. Raskob, Thomas M. Hyers, Alexander T. Cohen, Jeffrey I. Weitz, Harry R. Büller, Samuel Z. Goldhaber, Madelyn Curto and Margot Johnson and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Oncology.

In The Last Decade

Giancarlo Agnelli

174 papers receiving 13.3k citations

Hit Papers

Oral Apixaban for the Treatment of Acute Ven... 2001 2026 2009 2017 2013 2008 2001 2012 2004 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Oral Apixaban for the Treatment of Acute Venous Thromboembolism
    2013 1.7k citations Giancarlo Agnelli, Harry R. Büller et al. profile →
  2. Antithrombotic Therapy for Venous Thromboembolic Disease
    2008 1.4k citations Clive Kearon, Giancarlo Agnelli et al. profile →
  3. Antithrombotic Therapy for Venous Thromboembolic Disease
    2001 1.4k citations Giancarlo Agnelli et al. profile →
  4. Apixaban for Extended Treatment of Venous Thromboembolism
    2012 918 citations Giancarlo Agnelli, Harry R. Büller et al. profile →
  5. Antithrombotic Therapy for Venous Thromboembolic Disease
    2004 894 citations Giancarlo Agnelli, Martin H. Prins et al. profile →
  6. Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer
    2002 785 citations David Bergqvist, Giancarlo Agnelli et al. profile →
  7. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
    2009 446 citations Giancarlo Agnelli, Melina Verso et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Giancarlo Agnelli Italy 45 11.7k 8.7k 3.9k 2.6k 2.5k 180 13.9k
Michael R. Lassen Denmark 36 13.4k 1.1× 11.4k 1.3× 4.9k 1.2× 1.7k 0.7× 2.0k 0.8× 129 16.8k
Jeffrey S. Ginsberg Canada 67 12.2k 1.0× 9.4k 1.1× 5.4k 1.4× 2.1k 0.8× 5.1k 2.0× 208 16.5k
Anthonie W.A. Lensing Netherlands 41 9.2k 0.8× 6.8k 0.8× 3.1k 0.8× 2.0k 0.8× 2.7k 1.1× 91 11.0k
Graham F. Pineo Canada 34 8.9k 0.8× 7.2k 0.8× 4.2k 1.1× 1.5k 0.6× 1.6k 0.7× 116 12.1k
Manuel Monréal Spain 59 11.3k 1.0× 7.6k 0.9× 3.5k 0.9× 2.9k 1.1× 1.8k 0.7× 421 13.5k
William Geerts Canada 48 14.8k 1.3× 9.6k 1.1× 6.4k 1.6× 2.6k 1.0× 2.8k 1.1× 128 18.6k
Michael J. Kovacs Canada 32 8.4k 0.7× 5.8k 0.7× 2.6k 0.7× 1.9k 0.7× 2.1k 0.9× 101 10.6k
Marc Rodger Canada 62 9.9k 0.8× 6.6k 0.8× 3.3k 0.8× 1.7k 0.7× 3.9k 1.6× 271 14.6k
Russell D. Hull Canada 61 13.3k 1.1× 9.0k 1.0× 5.5k 1.4× 2.3k 0.9× 2.4k 1.0× 242 16.4k
Giancarlo Agnelli Italy 63 11.6k 1.0× 9.3k 1.1× 3.5k 0.9× 2.4k 1.0× 1.9k 0.8× 335 16.4k

Countries citing papers authored by Giancarlo Agnelli

Since Specialization
Citations

This map shows the geographic impact of Giancarlo Agnelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giancarlo Agnelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giancarlo Agnelli more than expected).

Fields of papers citing papers by Giancarlo Agnelli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giancarlo Agnelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giancarlo Agnelli. The network helps show where Giancarlo Agnelli may publish in the future.

Co-authorship network of co-authors of Giancarlo Agnelli

This figure shows the co-authorship network connecting the top 25 collaborators of Giancarlo Agnelli. A scholar is included among the top collaborators of Giancarlo Agnelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giancarlo Agnelli. Giancarlo Agnelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dagna, Lorenzo, Alessia Alunno, Nicola Farina, et al.. (2025). Assessment of cardiovascular, thromboembolic and cancer risk in patients eligible for treatment with Janus Kinase inhibitors: The JAK-ERA multidisciplinary consensus. European Journal of Internal Medicine. 134. 114–118.
2.
Cohen, Alexander T., Raza Alikhan, Jean M. Connors, et al.. (2024). Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer. Thrombosis and Haemostasis. 124(7). 676–683. 2 indexed citations
3.
Festari, Cristina, Cristina Bonomini, Sandra Rosini, et al.. (2024). Virtual Reality Combined With Psychoeducation to Improve Emotional Well‐Being in Informal Caregivers of Alzheimer's Disease Patients: Rationale and Study Design of a Randomized Controlled Trial. International Journal of Geriatric Psychiatry. 39(9). e6145–e6145. 5 indexed citations
4.
Verso, Melina, Andrés J. Muñoz Martín, & Giancarlo Agnelli. (2023). Bleeding risk with concomitant administration of VEGF-TKIs and anticoagulant agents. Seminars in Oncology. 50(3-5). 67–70. 1 indexed citations
5.
Ay, Cihan, Pieter W. Kamphuisen, & Giancarlo Agnelli. (2017). Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options. ESMO Open. 2(2). e000188–e000188. 29 indexed citations
6.
Torbicki, Adam, Arnaud Perrier, Stavros Konstantinides, et al.. (2016). GUIDELINES ON THE DIAGNOSIS AND MANAGEMENT OF ACUTE PULMONARY EMBOLISM. SHILAP Revista de lepidopterología. 1 indexed citations
7.
Kakkar, Ajay K., Giancarlo Agnelli, Winfield S. Fisher, et al.. (2013). Preoperative Enoxaparin Versus Postoperative Semuloparin Thromboprophylaxis in Major Abdominal Surgery. Annals of Surgery. 259(6). 1073–1079. 28 indexed citations
8.
Lassen, Michael R., Winfield S. Fisher, Patrick Mouret, et al.. (2012). Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE‐HIP1, SAVE‐HIP2 and SAVE‐KNEE. Journal of Thrombosis and Haemostasis. 10(5). 822–832. 20 indexed citations
9.
Becattini, Cecilia, et al.. (2012). Aspirin for Preventing the Recurrence of Venous Thromboembolism. Journal of Vascular Surgery. 56(4). 1179–1179. 1 indexed citations
10.
Agnelli, Giancarlo, Harry R. Büller, Alexander T. Cohen, et al.. (2012). Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism. Blood. 120(21). LBA–1. 5 indexed citations
11.
12.
Warwick, David, Richard J. Friedman, Giancarlo Agnelli, et al.. (2007). Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events. Journal of Bone and Joint Surgery - British Volume. 89-B(6). 799–807. 187 indexed citations
13.
14.
Filippucci, Esmeralda, et al.. (2004). Activation of blood coagulation in patients undergoing postoperative blood salvage and re-infusion of unwashed whole blood after total knee arthroplasty. Thrombosis Research. 113(3-4). 211–215. 14 indexed citations
15.
Raskob, Gary E., Clive Kearon, A. Planès, et al.. (2003). Evaluating bleeding complications of thromboprophylaxis after hip replacement: a systematic review. Journal of Thrombosis and Haemostasis. 1. P1860–P1860. 3 indexed citations
16.
Agnelli, Giancarlo & Francesco Sonaglia. (1998). Anticoagulant agents in the management of pulmonary embolism. International Journal of Cardiology. 65. S95–S98.
17.
Iorio, Alfonso & Giancarlo Agnelli. (1997). Pharmacokinetic Optimisation of the Treatment of Deep Vein Thrombosis. Clinical Pharmacokinetics. 32(2). 145–172. 11 indexed citations
18.
Iorio, Alfonso, et al.. (1997). Effect of Dermatan Sulphate on Activated Partial Thromboplastin Time Determined with Different Reagents. Pathophysiology of Haemostasis and Thrombosis. 27(2). 85–90. 3 indexed citations
19.
Imbimbo, Bruno P., Piérre Siè, Giancarlo Agnelli, et al.. (1994). Intramuscular Dermatan Sulfate MF701 in Patients with Hip Fracture: Relationship between Pharmacokinetics and Antithrombotic Efficacy. Thrombosis and Haemostasis. 71(5). 553–557. 7 indexed citations
20.
Agnelli, Giancarlo, et al.. (1991). Effects of Hirudin and Heparin on the Binding of New Fibrin to the Thrombus in t-PA Treated Rabbits. Thrombosis and Haemostasis. 66(5). 592–597. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael R. Lassen Breakdown of academic impact, for papers by Jeffrey S. Ginsberg Breakdown of academic impact, for papers by Anthonie W.A. Lensing Breakdown of academic impact, for papers by Graham F. Pineo Breakdown of academic impact, for papers by Manuel Monréal Breakdown of academic impact, for papers by William Geerts Breakdown of academic impact, for papers by Michael J. Kovacs Breakdown of academic impact, for papers by Marc Rodger Breakdown of academic impact, for papers by Russell D. Hull Breakdown of academic impact, for papers by Giancarlo Agnelli
Rankless by CCL
2026